These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90. Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome? Scarisbrick JJ J Invest Dermatol; 2020 Feb; 140(2):281-283. PubMed ID: 31980062 [TBL] [Abstract][Full Text] [Related]
91. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ; J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639 [TBL] [Abstract][Full Text] [Related]
92. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. Bi MY; Curry JL; Christiano AM; Hordinsky MK; Norris DA; Price VH; Duvic M J Am Acad Dermatol; 2011 Jan; 64(1):53-63. PubMed ID: 21036417 [TBL] [Abstract][Full Text] [Related]
93. Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. Golling P; Cozzio A; Dummer R; French L; Kempf W Leuk Lymphoma; 2008 Jun; 49(6):1094-103. PubMed ID: 18569636 [TBL] [Abstract][Full Text] [Related]
94. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401 [TBL] [Abstract][Full Text] [Related]
95. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update. Yamashita T; Abbade LP; Marques ME; Marques SA An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199 [TBL] [Abstract][Full Text] [Related]
96. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas. Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494 [TBL] [Abstract][Full Text] [Related]
97. Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides. Amorim GM; Corbellini JPN; Quintella DC; Cuzzi T; Ramos-E-Silva M An Bras Dermatol; 2018; 93(5):680-685. PubMed ID: 30156617 [TBL] [Abstract][Full Text] [Related]
98. Myocosis fungoides--an update on a non-mycotic disease. Makdisi J; Friedman A J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501 [TBL] [Abstract][Full Text] [Related]
99. Transformed mycosis fungoides: clinicopathological features and outcome. Barberio E; Thomas L; Skowron F; Balme B; Dalle S Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879 [TBL] [Abstract][Full Text] [Related]